Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

1724088

USP

Zanamivir

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminsäure

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C12H20N4O7
CAS-Nummer:
139110-80-8
Molekulargewicht:
332.31
MDL-Nummer:
MFCD00866966
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329751520
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

zanamivir

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O

InChI

1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1

InChIKey

ARAIBEBZBOPLMB-UFGQHTETSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Zanamivir USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem./physiol. Wirkung

Zanamivir is an influenza viral neuraminidase inhibitor.

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Piktogramme

Exclamation mark
GHS07

Signalwort

Warning

Gefahreneinstufungen

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Zielorgane

Respiratory system

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 6

1 of 6

Ribavirin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1700

Ribavirin

Mupirocin United States Pharmacopeia (USP) Reference Standard

USP

1448901

Mupirocin

Tobramycin United States Pharmacopeia (USP) Reference Standard

USP

1667508

Tobramycin

N-Acetyl-2,3-Dehydro-2-Desoxyneuraminsäure ≥93% (TLC)

Sigma-Aldrich

D9050

N-Acetyl-2,3-Dehydro-2-Desoxyneuraminsäure

Ribavirin antiviral

Sigma-Aldrich

R9644

Ribavirin

Mucin aus Rinderunterkieferdrüse Type I-S

Sigma-Aldrich

M3895

Mucin aus Rinderunterkieferdrüse

Xiaoli Xiong et al.
Virology, 456-457, 179-187 (2014-06-04)
Mutant H5N1 influenza viruses have been isolated from humans that have increased human receptor avidity. We have compared the receptor binding properties of these mutants with those of wild-type viruses, and determined the structures of their haemagglutinins in complex with
Susan Barrett et al.
Antiviral research, 108, 30-35 (2014-05-24)
The influenza virus neuraminidase inhibitors are normally slow binding inhibitors, but many mutations leading to resistance, also result in the loss of the slow binding phenotype. Mutations can also affect the rate of dissociation of the inhibitors from the neuraminidase
Ken Watanabe et al.
Archives of medical research, 45(5), 359-365 (2014-06-01)
Influenza viruses are a serious threat to human health and cause thousands of deaths annually. Thus, there is an urgent requirement for the development of novel anti-influenza virus drugs. Therefore, the aim of this study was to evaluate the anti-influenza
Kristin A Gabor et al.
Disease models & mechanisms, 7(11), 1227-1237 (2014-09-06)
Seasonal influenza virus infections cause annual epidemics and sporadic pandemics. These present a global health concern, resulting in substantial morbidity, mortality and economic burdens. Prevention and treatment of influenza illness is difficult due to the high mutation rate of the
Alireza Eshaghi et al.
Antimicrobial agents and chemotherapy, 58(12), 7188-7197 (2014-09-24)
Immunocompromised patients are predisposed to infections caused by influenza virus. Influenza virus may produce considerable morbidity, including protracted illness and prolonged viral shedding in these patients, thus prompting higher doses and prolonged courses of antiviral therapy. This approach may promote
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.